Evidence map›Paper›PMID 36561899›Full record

ArticlePublic health action2022

TB-related technical enquiries received in Japan, 2017-2019.

M Urakawa, A Yasukawa, Y Hoshino, M Ota, H Hatamoto, S Hirao, T Zama, Y Nagata, T Yoshiyama

Open access · diamondAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Public health action, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
0.4field-weighted citation impact, top 39% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed, 4 citations in OpenAlex.

  1. Article
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 1 institution in 1 country.

M UrakawaResearch Institute of Tuberculosis, Tokyo, Japan.
A YasukawaResearch Institute of Tuberculosis, Tokyo, Japan.
Y HoshinoResearch Institute of Tuberculosis, Tokyo, Japan.
M OtaResearch Institute of Tuberculosis, Tokyo, Japan.
H HatamotoResearch Institute of Tuberculosis, Tokyo, Japan.
S HiraoResearch Institute of Tuberculosis, Tokyo, Japan.
T ZamaResearch Institute of Tuberculosis, Tokyo, Japan.
Y NagataResearch Institute of Tuberculosis, Tokyo, Japan.
T YoshiyamaResearch Institute of Tuberculosis, Tokyo, Japan.
Japan Anti Tuberculosis Association · JP

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

settingJapan, an intermediate TB burden country.

objectiveTo review TB-related technical enquiries received at the Research Institute of Tuberculosis, Japan, from January 2017 to December 2019.

designThis was a cohort study.

resultsA total of 2,197 enquiries were analysed. On average, 61.0 enquiries/month (range: 42-81) were received. The enquiry rates were highest for the Yamanashi (4.65/100,000 population) and Ishikawa (4.55) Prefectures, and lowest in the Yamagata (0.46) and Tochigi (0.56) Prefectures. The main organisations the enquirers belonged to were local governments (

conclusionAs the most frequent enquiries were about diagnosis and treatment of TB, the health ministry of Japan should maintain a few specialised TB institutions with TB physicians to provide technical assistance.

Indexed as

enquiriesepidemiologyJapantechnical assistancetuberculosis

Identifiers

PMID36561899
PMCPMC9716821
OpenAlexW4310527923

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.